Natixis’s Mead Johnson Nutrition Company MJN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-474,376
Closed -$42.3M 1073
2017
Q1
$42.3M Buy
474,376
+57,181
+14% +$4.7M 0.53% 46
2016
Q4
$29.5M Buy
+417,195
New +$31.1M 0.3% 87
2015
Q4
Sell
-109,759
Closed -$7.73M 389
2015
Q3
$7.73M Buy
+109,759
New +$9.03M 0.16% 72
2014
Q4
Sell
-410,000
Closed -$39.5M 455
2014
Q3
$39.5M Buy
410,000
+307,466
+300% +$29.1M 0.61% 28
2014
Q2
$9.55M Buy
102,534
+1,234
+1% +$108K 0.11% 140
2014
Q1
$8.42M Sell
101,300
-67,371
-40% -$5.46M 0.11% 141
2013
Q4
$14.1M Sell
168,671
-166,329
-50% -$13.5M 0.12% 147
2013
Q3
$24.9M Buy
335,000
+175,000
+109% +$13.1M 0.27% 90
2013
Q2
$12.7M Buy
+160,000
New +$12.8M 0.18% 122

Other funds holding MJN

Natixis's MJN Position: Q2 2017 in Review

Natixis sold out of Mead Johnson Nutrition Company (MJN) in Q2 2017, closing a stake of 474,376 shares — an estimated $42.3M sold.

Natixis first reported a position in MJN in Q2 2013 and held it in 9 quarters. The position peaked at $42.3M in Q1 2017. 7 funds tracked by Wall St. Rank hold MJN as of Q2 2017.

  • Natixis reported no remaining Mead Johnson Nutrition Company position as of Q2 2017 after selling out during the quarter.
  • Natixis sold 474,376 Mead Johnson Nutrition Company shares in Q2 2017, an estimated $42.3M.
  • Natixis first reported a position in Mead Johnson Nutrition Company in Q2 2013 and held it in 9 quarters.
  • Natixis's Mead Johnson Nutrition Company position peaked at $42.3M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q2 2017.

Based on Natixis's 13F filing for Q2 2017, filed 14 Aug 2017.